Truist Securities Maintains Buy on Coherus BioSciences, Lowers Price Target to $22
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Robyn Karnauskas maintains a Buy rating on Coherus BioSciences (NASDAQ:CHRS) but lowers the price target from $24 to $22.
June 20, 2023 | 1:15 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Truist Securities maintains a Buy rating on Coherus BioSciences but lowers the price target from $24 to $22.
The news directly mentions Coherus BioSciences (CHRS) and the lowered price target by Truist Securities. While the Buy rating is maintained, the reduced price target may have a neutral impact on the stock price in the short term as it indicates a lower expected return, but still a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100